WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 307109

CAS#: 864821-90-9

Description: Eluxadoline, also known as JNJ-27018966, is a novel, orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use by the United States Food and Drug Administration on May 27, 2015. Eluxadoline is a μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system.

Price and Availability


USD 150
USD 1250
USD 3950

USD 350
USD 1950
USD 5950

USD 750
USD 2650
USD 13950

Eluxadoline, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 20 g may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 307109
Name: Eluxadoline
CAS#: 864821-90-9
Chemical Formula: C32H35N5O5
Exact Mass: 569.26382
Molecular Weight: 569.66
Elemental Analysis: C, 67.47; H, 6.19; N, 12.29; O, 14.04

Synonym: JNJ-27018966; JNJ27018966; JNJ 27018966; Eluxadoline, brand name: Viberzi.

IUPAC/Chemical Name: 5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid


InChi Code: InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1

SMILES Code: CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Gohil K. Pharmaceutical Approval Update. P T. 2015 Aug;40(8):493-532. PubMed PMID: 26236136; PubMed Central PMCID: PMC4517530.

2: Hornby PJ. Drug discovery approaches to irritable bowel syndrome. Expert Opin Drug Discov. 2015 Aug;10(8):809-24. doi: 10.1517/17460441.2015.1049528. PubMed PMID: 26193876.

3: Garnock-Jones KP. Eluxadoline: First Global Approval. Drugs. 2015 Jul;75(11):1305-10. doi: 10.1007/s40265-015-0436-4. PubMed PMID: 26149369.

4: Traynor K. Eluxadoline approved for irritable bowel syndrome with diarrhea. Am J Health Syst Pharm. 2015 Jul 1;72(13):1078. doi: 10.2146/news150043. PubMed PMID: 26092951.

5: Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May;55(5):534-42. doi: 10.1002/jcph.442. Epub 2015 Jan 14. PubMed PMID: 25491493; PubMed Central PMCID: PMC4402028.

6: Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub 2014 Sep 28. PubMed PMID: 25261794.

7: Andrae DA, Covington PS, Patrick DL. Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome. Clin Ther. 2014 May;36(5):663-79. doi: 10.1016/j.clinthera.2014.04.009. Epub 2014 May 9. PubMed PMID: 24813429.

8: Andrae DA, Patrick DL, Drossman DA, Covington PS. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. 2013 Dec 13;11:208. doi: 10.1186/1477-7525-11-208. PubMed PMID: 24330412; PubMed Central PMCID: PMC3895767.

9: Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9. PubMed PMID: 23583433.